We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 22, 2021

Circulating Tumour DNA in Patients With Advanced Melanoma Treated With Dabrafenib or Dabrafenib Plus Trametinib

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Circulating Tumour DNA in Patients With Advanced Melanoma Treated With Dabrafenib or Dabrafenib Plus Trametinib: A Clinical Validation Study
Lancet Oncol 2021 Feb 12;[EPub Ahead of Print], MM Syeda, JM Wiggins, BC Corless, GV Long, KT Flaherty, D Schadendorf, PD Nathan, C Robert, A Ribas, MA Davies, JJ Grob, E Gasal, M Squires, M Marker, J Garrett, JC Brase, D Polsky

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading